advertisement
Abstract #6879 Published in IGR 4-1
Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon SAmerican Journal of Ophthalmology 2002; 133: 11-18
PURPOSE: To assess, before and during oral nonsteroidal anti-inflammatory drug coadministration, latanoprost's and brimonidine's hypotensive action in eyes at risk of glaucomatous progression, assessing the effect of each drug on ocular perfusion and visual function. METHODS: Twenty consenting adults with open-angle glaucoma or ocular hypertension underwent a double-masked, bilateral, randomized prospective study. Treatment started with either latanoprost 0.005% in the morning and placebo in the evening, or brimonidine 0.2% twice daily in one eye; after one week starting the other in the fellow eye. After another week, oral indomethacin 25 mg four times a day, commenced for two more weeks. Intraocular pressure, ocular circulation, and visual function were monitored pretreatment, after unilateral monotherapy (Day 7), bilateral ocular therapy (Day 14), and coadministered oral indomethacin (Day 28). Intrasubject differences (interocular and intraocular relative to baseline) were determined by two-tailed paired t test. RESULTS: A loss of the significance of intraocular pressure reduction with brimonidine was noted after oral indomethacin coadministration (-14%; p = 0.004 for brimonidine alone versus -11%; p = 0.3 with indomethacin). Significant intraocular pressure (IOP) reduction with latanoprost persisted despite indomethacin (-25%; p
Dr. W.E. Sponsel, South Texas Ocular Imaging Center, University of Texas Health Science Center at San Antonio, Department of Ophthalmology, San Antonio, TX 78229-3900, USA. sponsel@uthscsa.edu
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
